-+ 0.00%
-+ 0.00%
-+ 0.00%

Pulse Biosciences to present one-year nsPFA atrial fibrillation study outcomes at HRS 2026

PUBT·04/20/2026 11:01:20
Listen to the news
Pulse Biosciences to present one-year nsPFA atrial fibrillation study outcomes at HRS 2026
  • Pulse Biosciences flagged late-breaking clinical trial updates on its nPulse Cardiac Catheter using nanosecond pulsed field ablation for atrial fibrillation at Heart Rhythm Society 2026 in Chicago on April 23-26.
  • One-year outcomes from a European feasibility study were already generated, with results scheduled for presentation on April 25.
  • The update is set to describe longer-term performance from a multicenter experience, supporting positioning of the technology in an increasingly competitive pulsed field ablation market.
  • Pulse also plans a live case transmission on April 23 to demonstrate procedural workflow and real-time use of the system in an atrial fibrillation setting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260420628292) on April 20, 2026, and is solely responsible for the information contained therein.